1.32
price up icon3.13%   0.04
after-market Dopo l'orario di chiusura: 1.35 0.03 +2.27%
loading
Precedente Chiudi:
$1.28
Aprire:
$1.16
Volume 24 ore:
257.16K
Relative Volume:
0.83
Capitalizzazione di mercato:
$82.85M
Reddito:
-
Utile/perdita netta:
$-45.08M
Rapporto P/E:
-1.8082
EPS:
-0.73
Flusso di cassa netto:
$-33.68M
1 W Prestazione:
-13.16%
1M Prestazione:
-16.98%
6M Prestazione:
-53.19%
1 anno Prestazione:
-56.00%
Intervallo 1D:
Value
$1.12
$1.32
Intervallo di 1 settimana:
Value
$1.12
$1.41
Portata 52W:
Value
$0.726
$4.2684

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name
Nome
Galectin Therapeutics Inc
Name
Telefono
678-620-3186
Name
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Name
Dipendente
14
Name
Cinguettio
@galectingalt
Name
Prossima data di guadagno
2025-03-31
Name
Ultimi documenti SEC
Name
GALT's Discussions on Twitter

Confronta GALT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
GALT
Galectin Therapeutics Inc
1.32 82.85M 0 -45.08M -33.68M -0.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-08-13 Reiterato H.C. Wainwright Buy
2019-02-13 Iniziato B. Riley FBR Buy
2017-12-07 Reiterato H.C. Wainwright Buy
2017-11-28 Reiterato H.C. Wainwright Buy
2017-10-19 Iniziato ROTH Capital Buy
2017-03-30 Aggiornamento H.C. Wainwright Neutral → Buy
2016-10-03 Downgrade FBR & Co. Outperform → Mkt Perform
2016-09-29 Downgrade H.C. Wainwright Buy → Neutral
2016-09-28 Downgrade ROTH Capital Buy → Sell
2016-03-28 Ripresa H.C. Wainwright Buy
2015-09-21 Iniziato H.C. Wainwright Buy
2014-08-01 Downgrade Aegis Capital Buy → Hold
2014-07-30 Reiterato MLV & Co Buy
2014-07-29 Reiterato MLV & Co Buy
2014-04-02 Reiterato MLV & Co Buy
2014-02-10 Reiterato Aegis Capital Buy
2014-01-09 Reiterato Aegis Capital Buy
2013-12-03 Iniziato MLV & Co Buy
2013-08-19 Reiterato Aegis Capital Buy
Mostra tutto

Galectin Therapeutics Inc Borsa (GALT) Ultime notizie

pulisher
09:31 AM

Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

09:31 AM
pulisher
08:16 AM

HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

08:16 AM
pulisher
02:52 AM

HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World

02:52 AM
pulisher
Apr 01, 2025

Galectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Galectin Therapeutics Reports Promising 2024 Results - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 21, 2025

Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com

Mar 21, 2025
pulisher
Mar 14, 2025

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail

Mar 14, 2025
pulisher
Mar 08, 2025

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance

Mar 08, 2025
pulisher
Mar 07, 2025

Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks

Mar 05, 2025
pulisher
Feb 26, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor - MSN

Feb 26, 2025
pulisher
Feb 20, 2025

Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World

Feb 20, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan

Feb 18, 2025
pulisher
Feb 15, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World

Feb 15, 2025
pulisher
Feb 04, 2025

Largest borrow rate increases among liquid names - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Feb 04, 2025
pulisher
Jan 30, 2025

Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve

Jan 30, 2025
pulisher
Jan 29, 2025

Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR

Jan 29, 2025
pulisher
Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Galectin drops as trial for lead asset fails in MASH - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 25, 2025

Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 25, 2025
pulisher
Jan 23, 2025

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 21, 2025

HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN

Jan 21, 2025
pulisher
Jan 18, 2025

Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

SouthState Corporation Announces Sale Agreement with Blue Owl Real Estate Capital On January 8, 2025, SouthState Bank, N.A., a subsidiary of SouthState Corporation, has entered into a significant agreement for the purchase and sale of real property w - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire

Jan 15, 2025
pulisher
Jan 11, 2025

Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World

Jan 10, 2025
pulisher
Jan 08, 2025

Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 08, 2025
pulisher
Jan 03, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World

Jan 03, 2025
pulisher
Dec 31, 2024

Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria

Dec 31, 2024
pulisher
Dec 31, 2024

Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL

Dec 31, 2024

Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Galectin Therapeutics Inc Azioni (GALT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Jamil Khurram
Chief Medical Officer
Dec 23 '24
Option Exercise
0.00
40,000
0
40,000
Jamil Khurram
Chief Medical Officer
Dec 23 '24
Sale
0.88
13,654
12,044
26,346
LEWIS JOEL
President and CEO
Dec 23 '24
Option Exercise
0.00
56,000
0
953,012
LEWIS JOEL
President and CEO
Dec 23 '24
Sale
0.89
56,000
49,610
897,012
CALLICUTT JACK W
Chief Financial Officer
Dec 23 '24
Option Exercise
0.00
40,000
0
47,614
CALLICUTT JACK W
Chief Financial Officer
Dec 23 '24
Sale
0.89
40,000
35,492
7,614
Zordani Richard A. Jr.
Director
Dec 24 '24
Buy
0.82
10,000
8,164
42,083
ELDRED KARY
Director
Dec 24 '24
Buy
0.82
13,469
11,045
63,682
FREEMAN KEVIN D
Director
Dec 24 '24
Buy
0.81
10,000
8,134
44,769
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):